So have pharmaceutical stocks weathered the storm, or is there more trouble to come?
In a note today, JP Morgan analyst Chris Schott suggests the hard rain isn’t about to let up:
“Faced with FDA uncertainty, a wave of upcoming patent expirations and mixed pipeline prospects, the group is no longer the defensive sector of the past,” [...]
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment